Chronix Biomedical
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Apr 2031
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 13, 2027The maintenance fee for Analyzing Circulating Nucleic Acids to Identify a Biomarker Representative of Cancer Presented by a Patient Population (US 10,378,064) comes due Feb 13, 2027. Unpaid by Aug 13, 2027, it lapses early.
- 1 fee due Jul 2, 2027The maintenance fee for Identifaction of Cancer Biomarkers by Alignment of Nucleic Acid Sequences (US 11,859,251) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 1 fee due Aug 25, 2027The maintenance fee for Methods of Quantifying Cell-Free DNA (US 10,570,443) comes due Aug 25, 2027. Unpaid by Feb 25, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 10 of 10
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,047,397 | Breast Cancer Associated Circulating Nucleic Acid Biomarkers In force · High confidence | In force | High confidence | |
| US 10,378,064 | Analyzing Circulating Nucleic Acids to Identify a Biomarker Representative of Cancer Presented by a Patient Population In force · High confidence | In force | High confidence | |
| US 11,859,251 | Identifaction of Cancer Biomarkers by Alignment of Nucleic Acid Sequences In force · High confidence | In force | High confidence | |
| US 11,377,695 | Breast Cancer Associated Circulating Nucleic Acid Biomarkers In force · High confidence | In force | High confidence | |
| US 11,414,706 | A Method of Determining a Numeric Index of Tumor-Associated Copy Number Changes of Circulating Nucleic Acids Associated with Prostate Cancer In force · High confidence | In force | High confidence | |
| US 9,909,186 | Personalized Biomarkers for Cancer In force · High confidence | In force | High confidence | |
| US 11,155,872 | Detection and Quantification of Donor Cell-Free DNA in the Circulation of Organ Transplant Recipients In force · High confidence | In force | High confidence | |
| US 10,214,775 | Prostate Cancer Associated Circulating Nucleic Acid Biomarkers In force · High confidence | In force | High confidence | |
| US 10,570,443 | Methods of Quantifying Cell-Free DNA In force · High confidence | In force | High confidence | |
| US 12,359,252 | Colorectal Cancer Associated Circulating Nucleic Acid Biomarkers In force · High confidence | In force | High confidence |
Also on record, not counted in the 10: 2 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
6 pending · 4 abandoned · 8 no status recorded